• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Natus Medical Finalizes Transition of Peloton Business to Pediatrix Medical Group and Completes Signing of Strategic Agreement

Share:

January 7, 2020

Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced that effective December 31, 2019 the Company has finalized and executed the previously announced transition of the Peloton hearing screening services business to Pediatrix Medical Group (“Pediatrix”).

Pediatrix Medical Group, a MEDNAX, Inc. company, will manage all newborn hearing screening services for Peloton hospitals while Natus will provide its best-in-class ALGO screeners and supplies to Pediatrix to support its entire hearing screening business. Installation of ALGO screeners at the Pediatrix hospitals is expected to be completed during 2020.

Source: BioSpace

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Health2Sync Partners with DAIKYO ASTAGE and Two Pharmacies to Pilot Health Management Services in JapanHealth2Sync Partners with DAIKYO ASTAGE and Two Pharmacies to Pilot Health Management Services in Japan
  • Wealthcraft Capital Repositions Its Strategy in Response to the 2018 Farm BillWealthcraft Capital Repositions Its Strategy in Response to the 2018 Farm Bill
  • Healthcare Consumers are Seeking Clear Communications, Tech-Enabled Access to CareHealthcare Consumers are Seeking Clear Communications, Tech-Enabled Access to Care
  • Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix HoldingsEluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings
  • Biotech PTC to acquire Lynnfield’s Agilis in $200M dealBiotech PTC to acquire Lynnfield’s Agilis in $200M deal
  • Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference CallProvention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
  • FDA Regulations Allow Medical Devices Clinical Trials to Differ From Pharmaceutical TrialsFDA Regulations Allow Medical Devices Clinical Trials to Differ From Pharmaceutical Trials
  • Oxurion Further Improves THR-149 Patent PositionOxurion Further Improves THR-149 Patent Position

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications